leisure time -WSS

leisure time

author：focus 2025-09-30 18:42:51 - browse：691

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： CDC recommends RSV monoclonal antibody for infants

focus

WSS

Pharma showers House GOP doctor with campaign cash

Pharma showers House GOP doctor with campaign cash

Illinois Supreme Court finds assault weapons ban constitutional

The a glaring gap in research on serious mental illness and primary care

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Schizophrenia gene found to be linked to cells' energy dysfunction

hotspot

leisure time

hotspot

Drug repurposing or repositioning? The language matters

Maui wildfire now ranks as the fifth

Guidelines to prevent youth baseball injuries need more muscle

YouTube cracks down on misinformation on cancer treatment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

Sports medicine is finally prioritizing gender equality

How I helped Pfizer think through the ethics of Viagra

The cancer drug shortage isn’t new — and neither are the solutions

Biden administration begins canceling student loan debt for 804,000 borrowers

hotspot

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

A controversial new treatment promises to make little people taller

After Optum profits sink, UnitedHealth makes changes

Biden administration begins canceling student loan debt for 804,000 borrowers

Pharma showers House GOP doctor with campaign cash

Biotech startup Celsius cuts 75% of staff ahead of first trial start

explore

focus

focus

hotspot